CONFORMAL RADIOACTIVE PLAQUES FOR INTRAOCULAR MELANOMA

治疗眼内黑色素瘤的适形放射性斑块

基本信息

  • 批准号:
    6384741
  • 负责人:
  • 金额:
    $ 45.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-04-01 至 2004-08-31
  • 项目状态:
    已结题

项目摘要

Radiation is the most frequently used eye and vision-sparing alternative to enucleation of eyes with choroidal melanoma. Brachytherapy, in the form of ophthalmic (radioactive) plaques (OP) is a successful approach for treatment of choroidal melanoma. While preserving vision and minimizing complications, ophthalmic plaque radiotherapy has offered excellent (>92%) local control rates. Current generation ophthalmic plaques, 60Co, 106Ru plates,125I, and 103pd seeds, are less than ideal for dose delivery, have a primitive design, involve antiquated and inefficient manufacturing procedures, and suffer from one or more deficiencies. We propose developing a new ophthalmic plaque based on a charged particle activation process, which allows for manufacturing a broad uniform source, directly embedded in a thin foil. This technology allows for automated custom manufacturing of OPs that match the source intensity to the topography of tumor. Such conformal radiation ophthalmic plaques (CROP) will maximize the tumor dose and minimize the unintentional dose to neighboring radiosensitive tissues. The Phase I application demonstrated feasibility of the process. Tearing arrangements have been made with a leading ophthalmologist and one of the champions of brachytherapy by OP to evaluate the clinical performance of the conformal radiation ophthalmic plaques and demonstrate the success of the project. PROPOSED COMMERCIAL APPLICATION: The market for ophthalmic plaques is small. The U.S. market for such a product is estimated to be around 1500 units/year. There are an equal number of patients overseas. If we assume each plaque uses up to 40 seeds at an average cost of $50 per seed and the associated assembly costs to be approximately $3000, the potential market for new generation OPs is $4,500,000 in the U.S. There is a market of approximately equal size for infants suffering from retinoblastoma where there is a dire need for a thin ophthalmic plaque. There is a sizeable potential market for the OPs for treatment of age related neovascularization.
对于脉络膜黑色素瘤患者的眼球摘除手术,放射治疗是最常用的眼部和视力保护方案。以眼部(放射性)斑块(OP)为形式的近距离放射治疗是治疗脉络膜黑色素瘤的成功方法。在保护视力和最大限度减少并发症的同时,眼斑放射治疗提供了出色的(92%)局部控制率。当前一代的眼科斑块,60Co、106Ru板、125I和103pd种子,不太适合剂量传递,设计原始,涉及过时和低效的制造工艺,并存在一个或多个缺陷。我们建议开发一种基于带电粒子激活过程的新的眼科斑块,该过程允许制造广泛的均匀源,直接嵌入薄片中。这项技术允许自动定制制造OP,使源强度与肿瘤的地形相匹配。这种适形放射眼斑(CROP)将使肿瘤剂量最大化,并将对邻近放射敏感组织的意外剂量降至最低。第一阶段的应用证明了该工艺的可行性。OP已经与一位领先的眼科医生和近距离放射治疗的领军者之一进行了撕裂安排,以评估适形放射眼斑的临床表现,并展示该项目的成功。拟议的商业应用:眼科斑块的市场很小。据估计,美国市场对这类产品的需求约为1500台/年。在海外也有同样数量的患者。如果我们假设每个斑块使用多达40个种子,每个种子的平均成本为50美元,相关的组装成本约为3000美元,则新一代OP的潜在市场在美国为450万美元。对于患有视网膜母细胞瘤的婴儿来说,存在着一个大致相同大小的市场,那里迫切需要一个薄的眼部斑块。OPS在治疗年龄相关性新生血管方面有相当大的潜在市场。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PIRAN SIOSHANSI其他文献

PIRAN SIOSHANSI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PIRAN SIOSHANSI', 18)}}的其他基金

Real-Time Image and Dose Guided Radiation Therapy System
实时图像和剂量引导放射治疗系统
  • 批准号:
    7480668
  • 财政年份:
    2008
  • 资助金额:
    $ 45.25万
  • 项目类别:
PATIENT OPTIMIZED BRACHYTHERAPY FOR BREAST CARCINOMA
针对乳腺癌患者的优化近距离治疗
  • 批准号:
    6298489
  • 财政年份:
    2001
  • 资助金额:
    $ 45.25万
  • 项目类别:
SKIN PATCHES FOR AIDS PATIENTS
艾滋病患者的皮肤贴片
  • 批准号:
    2776923
  • 财政年份:
    1999
  • 资助金额:
    $ 45.25万
  • 项目类别:
RADIOISOTOPE TREATED VASCULAR GRAFTS
放射性同位素处理的血管移植物
  • 批准号:
    6015760
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:
RADIONUCLIDE ION IMPLANTED CAPS FOR INTRAOCULAR MELANOMA
用于治疗眼内黑色素瘤的放射性核素离子植入帽
  • 批准号:
    2650432
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:
PROSTATE CANCER RADIONUCLIDE SOURCES BY ION IMPLANTATION
通过离子注入治疗前列腺癌放射性核素源
  • 批准号:
    2645333
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:
MINIMALLY INVASIVE PROBE FOR IN-VIVO DETECTION OF IRON
用于铁体内检测的微创探针
  • 批准号:
    6021602
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:
LINEAR PD SOURCES FOR PROSTATE BRACHYTHERAPY
用于前列腺近距离治疗的线性 PD 源
  • 批准号:
    6173669
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:
LINEAR PD SOURCES FOR PROSTATE BRACHYTHERAPY
用于前列腺近距离治疗的线性 PD 源
  • 批准号:
    6020305
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:
MINIMALLY INVASIVE PROBE FOR IN-VIVO DETECTION OF IRON
用于铁体内检测的微创探针
  • 批准号:
    2803537
  • 财政年份:
    1998
  • 资助金额:
    $ 45.25万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.25万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
  • 批准号:
    10762827
  • 财政年份:
    2023
  • 资助金额:
    $ 45.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了